ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with
June 22, 2021Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced initiation of a potential registration-enabling Phase 2 study of INBRX-109 in conventional chondrosarcoma. -
Inhibrx Announces Positive Interim Results from Chondrosarcoma Trial
November 24, 2020Inhibrx has announced updated interim results from a Phase 1 clinical trial evaluating the efficacy and safety of INBRX-109 in patients with chondrosarcoma. Chondrosarcoma is an orphan disease and bone cancer with approximately 2,800 new patients ...
Pharma Sources Insight January 2025
